{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:38:58Z","timestamp":1792535938961,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"DOI":"10.1007\/s11886-026-02430-z","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:21:51Z","timestamp":1792488111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Fixed-Dose Combination Therapies on Cardiovascular Mortality and Major Cardiovascular Events"],"prefix":"10.1007","volume":"28","author":[{"given":"Jia Ee","family":"Chia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunseuk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Peng","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"3","key":"2430_CR1","first-page":"Cd009868","volume":"3","author":"E Bahiru","year":"2017","unstructured":"Bahiru E, de Cates AN, Farr MR, Jarvis MC, Palla M, Rees K, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;3(3):Cd009868.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2430_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1161\/01.CIR.0000112577.69066.CB","volume":"109","author":"D Mukherjee","year":"2004","unstructured":"Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109(6):745\u20139.","journal-title":"Circulation"},{"key":"2430_CR3","doi-asserted-by":"crossref","unstructured":"Mukherjee D, Mani S. Improving individual lifetime cardiovascular disease risk estimation to optimize secondary prevention. Eur Heart J. 2026:ehag479.","DOI":"10.1093\/eurheartj\/ehag479"},{"issue":"9326","key":"2430_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0140-6736(02)09358-3","volume":"360","author":"S Yusuf","year":"2002","unstructured":"Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002;360(9326):2\u20133.","journal-title":"Lancet"},{"issue":"20","key":"2430_CR5","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.109.873232","volume":"122","author":"E Lonn","year":"2010","unstructured":"Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases. Circulation. 2010;122(20):2078\u201388.","journal-title":"Circulation"},{"issue":"7404","key":"2430_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","volume":"326","author":"NJ Wald","year":"2003","unstructured":"Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419.","journal-title":"BMJ"},{"issue":"3","key":"2430_CR7","first-page":"16460","volume":"133","author":"A Coca","year":"2023","unstructured":"Coca A, Castellano JM, Camafort M, Fuster V. Polypill in cardiovascular disease prevention: recent advances. Pol Arch Intern Med. 2023;133(3):16460.","journal-title":"Pol Arch Intern Med"},{"issue":"5","key":"2430_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11886-024-02046-1","volume":"26","author":"A De la Rosa","year":"2024","unstructured":"De la Rosa A, Arrington K, Desai R, Acharya PC. Polypill strategy in secondary cardiovascular prevention. Curr Cardiol Rep. 2024;26(5):443\u201350.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"2430_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.aogh.2013.12.008","volume":"80","author":"B Wiley","year":"2014","unstructured":"Wiley B, Fuster V. The concept of the polypill in the prevention of cardiovascular disease. Ann Glob Health. 2014;80(1):24\u201334.","journal-title":"Ann Glob Health"},{"issue":"6921","key":"2430_CR10","first-page":"81","volume":"308","author":"Collaborative overview of","year":"1994","unstructured":"Collaborative overview of. randomised trials of antiplatelet therapy\u2013I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collab Bmj. 1994;308(6921):81\u2013106.","journal-title":"Antiplatelet Trialists\u2019 Collab Bmj"},{"issue":"43","key":"2430_CR11","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1093\/eurheartj\/ehac518","volume":"43","author":"G Liuzzo","year":"2022","unstructured":"Liuzzo G, Patrono C. A SECURE polypill as a strategy at the heart of secondary prevention. Eur Heart J. 2022;43(43):4534\u20135.","journal-title":"Eur Heart J"},{"issue":"9672","key":"2430_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(09)60611-5","volume":"373","author":"S Yusuf","year":"2009","unstructured":"Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373(9672):1341\u201351.","journal-title":"Lancet"},{"issue":"1","key":"2430_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.recesp.2019.11.021","volume":"74","author":"JR Gonz\u00e1lez-Juanatey","year":"2021","unstructured":"Gonz\u00e1lez-Juanatey JR, Tamargo J, Torres F, Weisser B, Oudovenko N. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Rev Esp Cardiol (Engl Ed). 2021;74(1):51\u20138.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"Suppl 1","key":"2430_CR14","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/S0167-5273(15)31028-7","volume":"201","author":"J Tamargo","year":"2015","unstructured":"Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol. 2015;201(Suppl 1):S15\u201322.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2430_CR15","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2013.277064","volume":"310","author":"S Thom","year":"2013","unstructured":"Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918\u201329.","journal-title":"JAMA"},{"issue":"20","key":"2430_CR16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","volume":"64","author":"JM Castellano","year":"2014","unstructured":"Castellano JM, Sanz G, Pe\u00f1alvo JL, Bansilal S, Fern\u00e1ndez-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"10199","key":"2430_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S0140-6736(19)31791-X","volume":"394","author":"G Roshandel","year":"2019","unstructured":"Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672\u201383.","journal-title":"Lancet"},{"issue":"3","key":"2430_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1056\/NEJMoa2028220","volume":"384","author":"S Yusuf","year":"2021","unstructured":"Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216\u201328.","journal-title":"N Engl J Med"},{"issue":"11","key":"2430_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1056\/NEJMoa2208275","volume":"387","author":"JM Castellano","year":"2022","unstructured":"Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022;387(11):967\u201377.","journal-title":"N Engl J Med"},{"issue":"8","key":"2430_CR20","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1038\/s41591-026-04504-5","volume":"32","author":"A Pandey","year":"2026","unstructured":"Pandey A, Keshvani N, Rizvi SK, Khashami F, Yaros K, Usman MS, et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. 2026;32(8):2933\u201340.","journal-title":"Nat Med"},{"issue":"10306","key":"2430_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","volume":"398","author":"P Joseph","year":"2021","unstructured":"Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133\u201346.","journal-title":"Lancet"},{"key":"2430_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.amjcard.2023.06.001","volume":"201","author":"R Sedhom","year":"2023","unstructured":"Sedhom R, Hamed M, Tan W, Mansoor H, Stoletniy L, Mamas M, et al. Meta-analysis on the clinical outcomes with polypills for cardiovascular disease prevention. Am J Cardiol. 2023;201:211\u20138.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2430_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-024-02896-w","volume":"30","author":"A Agarwal","year":"2024","unstructured":"Agarwal A, Mehta PM, Jacobson T, Shah NS, Ye J, Zhu J, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease. Nat Med. 2024;30(4):1199\u2013209.","journal-title":"Nat Med"},{"issue":"1","key":"2430_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijcard.2013.10.007","volume":"170","author":"R Webster","year":"2013","unstructured":"Webster R, Patel A, Billot L, Cass A, Burch C, Neal B, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. Int J Cardiol. 2013;170(1):30\u20135.","journal-title":"Int J Cardiol"},{"issue":"12","key":"2430_CR25","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"38","key":"2430_CR26","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"key":"2430_CR27","volume-title":"The selection and use of essential medicines 2023: web annex A, world health organization model list of essential medicines, 23rd list. Web Annex A","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. The selection and use of essential medicines 2023: web annex A, world health organization model list of essential medicines, 23rd list. Web Annex A. Geneva: World Health Organization; 2023."},{"issue":"1","key":"2430_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5334\/gh.1457","volume":"20","author":"EG Ferro","year":"2025","unstructured":"Ferro EG, Satheesh G, Castellano J, Damasceno A, Erojikwe O, Huffman M, et al. WHF roadmap on single pill combination therapies. Glob Heart. 2025;20(1):73.","journal-title":"Glob Heart"},{"issue":"8","key":"2430_CR29","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1038\/s41591-026-04504-5","volume":"32","author":"A Pandey","year":"2026","unstructured":"Pandey A, Keshvani N, Rizvi SK, Khashami F, Yaros K, Usman MS, et al. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial. Nat Med. 2026;32(8):2933\u201340.","journal-title":"Nat Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02430-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:01:58Z","timestamp":1792533718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02430-z","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"29 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence (AI) tools were used solely for language and grammar editing to improve the clarity and readability of the manuscript. No content, data analysis, interpretation, conclusions, or original manuscript content was generated using AI.","order":3,"name":"Ethics","label":"Use of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"113"}}